Elutia Inc. (ELUT)
The price, the headline numbers and the latest news, in one place.
Elutia Inc. (ELUT) Stock Price, Analysis & Data
| Bid | 0.64 |
| Market Cap | 38.97M |
| Revenue (ttm) | 12.14M |
| Net Income (ttm) | -22.43M |
| 0.88 | |
| -0.63 | |
| n/a | |
| -0.8 | |
| P/B (ttm) | 2.47 |
| P/S (ttm) | 3.21 |
| Earnings Date | Nov 12, 2026 |
| Ask | 1.14 |
| Volume | 138,623 |
| Avg. Volume (20D) | 84,855 |
| Open | 0.91 |
| Previous Close | 0.88 |
| Day's Range | 0.87 - 0.94 |
| 52-Week Range | 0.50 - 2.38 |
| Analyst | n/a |
| Price Target | 5 (468.18%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tis...
Financial Performance
In 2025, Elutia's revenue was 12.29M, a decrease of -15.03% compared to the previous year's 14.47M. Earnings were 53.38M, a decrease of -198.95%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for ELUT stock is "null". The 12-month stock price forecast is 5, which is upside of 468.18% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $3.11M misses estimates by $0, with 5.52% YoY growth.
- EPS of -0.17 misses estimates by -0.02, with 26.09% YoY growth.
Analysts project revenue of ... Upgrade
